This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
A conventional tablet of mirtazapine was introduced for treatment of depression in the mid-1990s. In February 2003, a new formulation of mirtazapine, the orally disintegrating tablet Remeron-S, was introduced in Sweden. The rationale is that patients experiencing difficulties in swallowing could let this new formulation melt before swallowing.1
In Sweden, health care professionals with permission to prescribe drugs, should report suspected adverse drug reactions (ADRs) to the regulatory authority, the Medical Product Agency, and the data are transferred online to the Swedish database (SWEDIS) for ADRs. The main aim of spontaneous reporting systems, such as the one in Sweden, is to produce signals regarding new potential ADRs.
Methods.
We examined all ADR reports in the SWEDIS database related to the conventional mirtazapine (Remeron), as well as those related to the orally disintegrating tablet (Remeron-S) that had been transferred to the database from January 1996 to September 2004. Furthermore, we compared these with other substances that had high total numbers of reports of paresthesia, and related to drug consumption measured as the number of defined daily doses (DDD). In brief, “DDD is the assumed average maintenance dose per day for a drug used for its main …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
